MARKET

TBIO

TBIO

Telesis Bio
NASDAQ
0.3214
+0.0001
+0.03%
After Hours: 0.3351 +0.0137 +4.26% 19:47 04/25 EDT
OPEN
0.3285
PREV CLOSE
0.3213
HIGH
0.3400
LOW
0.3121
VOLUME
26.91K
TURNOVER
0
52 WEEK HIGH
3.010
52 WEEK LOW
0.2997
MARKET CAP
9.68M
P/E (TTM)
-0.1957
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Tevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. Fresh2 Group stock rose 10.61% and ResMed stock rose 6.85% in the same session. The company's Q3 earnings came out today.
Benzinga · 10h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Acrivon Therapeutics stock rose 12.3% to $10.67 during Wednesday's after-market session. The company's, Q1 earnings came out today. Amarin Corp stock moved upwards by 8.12% and Universe Pharmaceuticals stock rose 7.47% in the same session.
Benzinga · 1d ago
Weekly Report: what happened at TBIO last week (0415-0419)?
Weekly Report · 3d ago
Telesis Bio announces leadership transition amid new commercial focus
Seeking Alpha · 04/18 16:14
Telesis Bio Inc. Announces Strategic Focus On Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform And BioXp mRNA Solutions; Todd R. Nelson To Step Down As CEO, Eric Esser, President And COO Of Telesis Bio, Will Assume The Role Of The Co's CEP, Effective Immediately
Telesis Bio Inc. Is a leader in automated benchtop DNA and mRNA synthesis solutions. The company's Gibson SOLA platform can deliver on-demand synthesis in 1 – 2 days. Telesis Bio will focus its efforts on the BioXp automation platform on mRNA synthesis workflows. Todd Nelson, the company's CEO, will no longer be the CEO of the company.
Benzinga · 04/18 13:17
Telesis Bio Leadership Shake-Up and Board Expansion
TipRanks · 04/18 13:13
TELESIS BIO INC - ON APRIL 16 BOARD APPROVED EXPANSION OF BOARD FROM SEVEN TO EIGHT MEMBERS
Reuters · 04/18 13:13
TELESIS BIO INC - ERIC ESSER, PRESIDENT AND COO OF TELESIS BIO, WILL ASSUME ROLE OF COMPANY'S CEO AND WILL JOIN COMPANY'S BOARD
Reuters · 04/18 13:00
More
About TBIO
Telesis Bio Inc. is a provider of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) solutions. The Company provides automated multi-omic and synthetic biology solutions focused on providing applications to enable researchers to rapidly and reproducibly build or write high-quality synthetic DNA and messenger Ribonucleic Acid (mRNA) and short oligonucleotides that are ready to use in many downstream synthetic biology enabled markets. Its BioXp system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. Its on-market and its planned solutions include BioXp 3250 system, BioXp 9600 system, BioXp portal, BioXp De Novo kits, BioXp Select kits, BioXp Next Generation Sequencing kits, Benchtop reagents and Custom Gibson Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis (EDS) solutions. BioXp Select kits offer customers the ability to use non-Telesis Bio DNA while using the BioXp system to perform synthetic biology workflow applications.

Webull offers Telesis Bio Inc stock information, including NASDAQ: TBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TBIO stock methods without spending real money on the virtual paper trading platform.